Moderna's decision to focus on oncology marks a significant strategic shift, potentially altering its market dynamics and investment landscape.
The FDA's fast-track designation for Janssen underscores the competitive pressures within the sector, raising questions about Moderna's positioning.
Investors should consider the second-order effects of this pivot, including the potential for increased volatility and the need for careful capital allocation.